EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 121.08

Change

-0.16 (-0.13)%

Market Cap

USD 0.70B

Volume

8.59K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+1.12 (+2.20%)

USD 501.76B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.35 (+2.11%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.53 (+1.97%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.62 (+2.20%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.54 (+2.19%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+3.00 (+2.11%)

USD 101.19B
JARI:XETRA Amundi Index Solutions - Amund..

+0.83 (+1.80%)

USD 100.74B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+1.06 (+2.08%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-0.72 (-0.13%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.43 (+1.86%)

USD 79.79B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.68% 72% C 72% C
Dividend Return 1.17% 40% F 27% F
Total Return 15.85% 75% C 73% C
Trailing 12 Months  
Capital Gain 14.42% 47% F 51% F
Dividend Return 1.41% 37% F 25% F
Total Return 15.83% 50% F 53% F
Trailing 5 Years  
Capital Gain 43.89% 63% D 65% D
Dividend Return 5.53% 62% D 33% F
Total Return 49.42% 67% D+ 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.39% 56% F 56% F
Dividend Return 7.32% 60% D- 57% F
Total Return 0.93% 63% D 43% F
Risk Return Profile  
Volatility (Standard Deviation) 8.42% 65% D 72% C
Risk Adjusted Return 87.01% 89% A- 90% A-
Market Capitalization 0.70B 71% C- 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike